Kala Reports Positive Results for Phase III Trial of KPI-121 for Post-Cataract Surgery Pain, Inflammation

May 12, 2017: By Jon Swedien

KalaA confirmatory Phase III trial for Kala Pharmaceuticals’ product candidate for post-cataract surgery pain and inflammation produced positive topline results, the Waltham, Massachusetts, company announced May 1.

KPI-121 is a novel nanoparticle formulation of loteprednol etabonate using Kala’s mucus-penetrating particle technology to enhance penetration into tissues of the eye.

The company said it intends to submit a new drug application to the US FDA in late 2017.

In the Phase III multicenter, randomized, double-masked trial of 520 patients, KPI-121 1% was dosed twice daily for two weeks and achieved statistical significance versus placebo for both primary efficacy endpoints and all secondary endpoints, Kala said.

The primary efficacy endpoints were the proportion of patients with complete resolution of anterior chamber cells—a marker of ocular inflammation—in the study eye at day eight, and the proportion of subjects with grade zero pain in the study eye at day eight, Kala said.

Secondary endpoints were complete resolution of anterior chamber flare at day four, complete resolution of pain at day four, and mean change in anterior chamber cells at day four. Each case maintained through day 15 with no need for rescue medication, Kala said.

The positive results followed Kala’s first Phase III trial for KPI-121 1% for post-cataract surgery pain and inflammation that concluded in 2015. In 380 patients, the treatment achieved complete resolution of ocular pain by the eighth day of treatment.

Kala also is studying KPI-121’s effectiveness as a proposed dry eye treatment in a pair of Phase III trials, expected to be completed by the end of 2017.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022